Literature DB >> 15938993

Pharmacologic agents associated with QT interval prolongation.

Keith M Olsen1.   

Abstract

Diverse classes of medications are associated with QT interval prolongation and expose patients to the risk of potentially fatal ventricular arrhythmias. Clinicians can minimize adverse events by avoiding prescription of multiple medications associated with QT interval prolongation in high-risk patients.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15938993

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


  3 in total

1.  The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys.

Authors:  T M Haushalter; G S Friedrichs; D L Reynolds; M Barecki-Roach; G Pastino; R Hayes; A S Bass
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 2.  Cardiovascular considerations in antidepressant therapy: an evidence-based review.

Authors:  Habibeh Yekehtaz; Mehdi Farokhnia; Shahin Akhondzadeh
Journal:  J Tehran Heart Cent       Date:  2013-10-28

3.  Impaired Inactivation of L-Type Ca2+ Current as a Potential Mechanism for Variable Arrhythmogenic Liability of HERG K+ Channel Blocking Drugs.

Authors:  Jae Gon Kim; Dong Jun Sung; Hyun-ji Kim; Sang Woong Park; Kyung Jong Won; Bokyung Kim; Ho Chul Shin; Ki-Suk Kim; Chae Hun Leem; Yin Hua Zhang; Hana Cho; Young Min Bae
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.